Ecopipam as a pharmacologic treatment of stuttering
- PMID:31369655
Ecopipam as a pharmacologic treatment of stuttering
Abstract
Background: Stuttering, also known as childhood-onset fluency disorder, is a chronic neurodevelopmental disorder that affects 1% of the population and can greatly impact an individual's social, occupational, and academic functioning. Prior research has shown dopamine D2 antagonists are effective in reducing the severity of stuttering symptoms, but these compounds can be associated with metabolic and movement disorder adverse effects. Ecopipam is an investigational medication that acts as a selective dopamine D1 receptor antagonist. This mechanism should reduce the likelihood of metabolic and movement disorder adverse effects of D2 antagonists.
Method: This open-label pilot study investigated ecopipam in the treatment of adults who stutter.
Results: The results showed that a majority of participants demonstrated improvement in their stuttering. The medication was well tolerated.
Conclusions: These positive, preliminary findings suggest that a doubleblind, randomized controlled clinical trial to examine the efficacy of ecopipam in the treatment of stuttering is warranted.
Similar articles
- The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis.Maguire GA, Nguyen DL, Simonson KC, Kurz TL.Maguire GA, et al.Front Neurosci. 2020 Mar 27;14:158. doi: 10.3389/fnins.2020.00158. eCollection 2020.Front Neurosci. 2020.PMID:32292321Free PMC article.Review.
- A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease.Khasnavis T, Reiner G, Sommerfeld B, Nyhan WL, Chipkin R, Jinnah HA.Khasnavis T, et al.Mol Genet Metab. 2016 Apr;117(4):401-6. doi: 10.1016/j.ymgme.2016.02.005. Epub 2016 Feb 18.Mol Genet Metab. 2016.PMID:26922636Clinical Trial.
- Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans.Haney M, Ward AS, Foltin RW, Fischman MW.Haney M, et al.Psychopharmacology (Berl). 2001 Jun;155(4):330-7. doi: 10.1007/s002130100725.Psychopharmacology (Berl). 2001.PMID:11441422Clinical Trial.
- Cocaine-like subjective effects of nicotine are not blocked by the D1 selective antagonist ecopipam (SCH 39166).Chausmer AL, Smith BJ, Kelly RY, Griffiths RR.Chausmer AL, et al.Behav Pharmacol. 2003 Mar;14(2):111-20. doi: 10.1097/00008877-200303000-00002.Behav Pharmacol. 2003.PMID:12658071Clinical Trial.
- A double-blind, placebo-controlled, crossover trial of the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease.Khasnavis T, Torres RJ, Sommerfeld B, Puig JG, Chipkin R, Jinnah HA.Khasnavis T, et al.Mol Genet Metab. 2016 Jul;118(3):160-166. doi: 10.1016/j.ymgme.2016.04.012. Epub 2016 Apr 24.Mol Genet Metab. 2016.PMID:27179999Clinical Trial.
Cited by
- Speech Fluency Improvement in Developmental Stuttering Using Non-invasive Brain Stimulation: Insights From Available Evidence.Busan P, Moret B, Masina F, Del Ben G, Campana G.Busan P, et al.Front Hum Neurosci. 2021 Aug 11;15:662016. doi: 10.3389/fnhum.2021.662016. eCollection 2021.Front Hum Neurosci. 2021.PMID:34456692Free PMC article.Review.
- The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis.Maguire GA, Nguyen DL, Simonson KC, Kurz TL.Maguire GA, et al.Front Neurosci. 2020 Mar 27;14:158. doi: 10.3389/fnins.2020.00158. eCollection 2020.Front Neurosci. 2020.PMID:32292321Free PMC article.Review.
- Dopamine, vocalization, and astrocytes.Turk AZ, Lotfi Marchoubeh M, Fritsch I, Maguire GA, SheikhBahaei S.Turk AZ, et al.Brain Lang. 2021 Aug;219:104970. doi: 10.1016/j.bandl.2021.104970. Epub 2021 Jun 5.Brain Lang. 2021.PMID:34098250Free PMC article.
- Stuttering as a spectrum disorder: A hypothesis.SheikhBahaei S, Millwater M, Maguire GA.SheikhBahaei S, et al.Curr Res Neurobiol. 2023 Nov 1;5:100116. doi: 10.1016/j.crneur.2023.100116. eCollection 2023.Curr Res Neurobiol. 2023.PMID:38020803Free PMC article.Review.